# Drug of interest
My drug of interest is Doxycycline.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. ABCB1 (z: 2.14)
2. ABCC2 (z: 1.65)
3. CYP2D7 (z: 0.66)
4. CYP2D6 (z: 0.6)
5. ABCB4 (z: 0.59)
6. ABCG2 (z: 0.56)
7. SLCO1B1 (z: 0.54)
8. CYP3A4 (z: 0.5)
9. CYP2C19 (z: 0.49)
10. HLA-B (z: 0.45)
11. ABCC3 (z: 0.36)
12. ABCC4 (z: 0.33)
13. HLA-A (z: 0.31)
14. CYP2S1 (z: 0.31)
15. SLC22A1 (z: 0.29)
16. CES1 (z: 0.28)
17. HLA-C (z: 0.28)
18. SLC22A8 (z: 0.28)
19. IGF2-AS (z: 0.26)
20. CYP3A5 (z: 0.26)
21. SLC22A10 (z: 0.25)
22. G6PD (z: 0.24)
23. HLA-E (z: 0.24)
24. SLC22A7 (z: 0.23)
25. HLA-G (z: 0.22)
26. CYP2C9 (z: 0.22)
27. HLA-DRA (z: 0.22)
28. HLA-DRB1 (z: 0.22)
29. ABCC5 (z: 0.22)
30. SLC22A13 (z: 0.21)
31. NR1I2 (z: 0.2)
32. RUNDC3B (z: 0.2)
33. HLA-DQB1 (z: 0.2)
34. SLCO1B3 (z: 0.19)
35. CYP2J2 (z: 0.18)
36. ABCC1 (z: 0.18)
37. SLC22A9 (z: 0.18)
38. ABCC11 (z: 0.18)
39. NAT2 (z: 0.18)
40. HLA-DQA1 (z: 0.18)
41. CYP21A2 (z: 0.18)
42. SLC22A11 (z: 0.17)
43. CYP2R1 (z: 0.16)
44. ABCB11 (z: 0.16)
45. HFE (z: 0.15)
46. CYP2C8 (z: 0.15)
47. SLC2A9 (z: 0.15)
48. HLA-DPB1 (z: 0.15)
49. CYP4B1 (z: 0.15)
50. HLA-DPA1 (z: 0.15)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**Doxycycline**: Doxycycline's effectiveness and safety may be influenced by genetic variants in MATE proteins, which affect the renal excretion of the drug, altering its blood levels and potentially its efficacy or toxicity. Despite the drug's primary elimination path being fecal, and only partial urinary excretion, these genetic factors primarily impact the pharmacokinetics of doxycycline, specifically its clearance.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drugâ€™s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**SLCO1B1**: The SLCO1B1 gene, which facilitates the hepatic uptake of drugs, exhibits polymorphisms like c.521T>C that affect the pharmacokinetics of multiple drugs including statins, repaglinide, and rifampin, potentially leading to increased drug plasma concentrations, altered efficacy, and toxicity. This variability in drug transport efficiency necessitates adjustments in dosing to optimize therapeutic outcomes and minimize adverse effects for drugs such as simvastatin, atorvastatin, and others.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**HLA-B**: The HLA-B gene plays a crucial role in drug hypersensitivity reactions through allele-specific interactions, such as the HLA-B*57:01 allele causing severe reactions to abacavir and the HLA-B*15:02 allele being associated with severe adverse reactions to carbamazepine. These interactions, which involve the immune system's response to drug-modified peptides or the drug itself presented by the HLA-B protein, emphasize the importance of genetic testing in precision medicine to tailor drug therapy and minimize adverse reactions based on individual genetic profiles.

**ABCC3**: The ABCC3 gene significantly influences the pharmacokinetics and pharmacodynamics of drugs such as methotrexate and morphine by affecting their transport. Variants in ABCC3 can lead to altered excretion of methotrexate, which affects its effectiveness and side effects, and can modify the transport of morphine and its metabolites, impacting their systemic and neurological effects. Other chemotherapy drugs like doxorubicin and vincristine may also interact with ABCC3, potentially influencing drug efficacy and resistance through effects on drug efflux.

**ABCC4**: ABCC4 gene variants influence the pharmacokinetics and efficacy of various drugs by modulating their efflux from cells, which impacts drug concentrations in the body. This gene affects a wide range of drugs including cancer treatments (doxorubicin, methotrexate), antiretrovirals (zidovudine, tenofovir), and medications used in cardiovascular diseases and immune disorders (clopidogrel, azathioprine), potentially leading to variable therapy outcomes and drug resistance.

**HLA-A**: The HLA-A gene is crucial in pharmacogenetic interactions due to its role in immune-mediated hypersensitivity reactions to certain drugs. For instance, the HLA-A*31:01 allele increases the risk of severe skin reactions to carbamazepine, while the HLA-A*02:01 allele is linked to severe adverse reactions to allopurinol, both through mechanisms involving the immune system's response to these drugs or their metabolites. Other drugs such as abacavir, phenytoin, and flucloxacillin among others are also implicated in similar immune responses based on the HLA-A gene variations, affecting drug pharmacodynamics rather than pharmacokinetics.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**SLC22A1**: The gene SLC22A1, encoding for the organic cation transporter 1 (OCT1), significantly influences the absorption and distribution of various drugs, such as metformin, tramadol, lamotrigine, ondansetron, rasagiline, and imatinib, by affecting their hepatic uptake. Genetic variations in SLC22A1 can lead to different efficacy and safety profiles for these drugs, necessitating potential dosage adjustments in the management of conditions like diabetes, pain, epilepsy, nausea, Parkinsonâ€™s disease, and chronic myeloid leukemia.

**CES1**: CES1, or Carboxylesterase 1, plays a pivotal role in the metabolism of various drugs by hydrolyzing ester and amide bonds, affecting both the therapeutic efficacy and safety. For instance, genetic variations in CES1 can alter the activation rate of clopidogrel into its effective antiplatelet form and affect the metabolism of methylphenidate used in ADHD, impacting drug effectiveness and side effects. Additionally, CES1 converts prodrugs like enalapril and oseltamivir into active metabolites, and also influences the metabolism of drugs like heroin and sacubitril, which are critical for their therapeutic action and potential toxicity.

**HLA-C**: HLA-C plays a crucial role in drug hypersensitivity reactions, primarily through immune response mechanisms influenced by its polymorphic nature. The presence of the HLA-C*06:02 allele, for example, is strongly associated with hypersensitivity to abacavir, used in HIV treatment, necessitating genetic screening to prevent severe reactions. Other drugs such as carbamazepine, allopurinol, clozapine, and phenytoin also show interactions with various HLA alleles that might contribute to adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.

**SLC22A8**: Cefotaxime's clearance is influenced by genetic variations in the SLC22A8 gene, which encodes the Organic Anion Transporter 3 (OAT3) responsible for its renal excretion. These variations can lead to altered drug levels in the body, thereby affecting the efficacy and safety of cefotaxime, particularly in patients with renal impairment.

**IGF2-AS**: The IGF2-AS gene, by modulating IGF2 expression through its antisense RNA, influences the effectiveness and safety of drugs like growth hormone replacements and insulin therapies which target the insulin-like growth factor pathway. Alterations in IGF2-AS can lead to varied responses to these treatments, necessitating adjustments in drug dosages and approaches to maximize efficacy and minimize adverse effects in conditions like growth hormone deficiencies and diabetes.

**CYP3A5**: CYP3A5 plays a key role in the metabolism of several drugs, including immunosuppressants like tacrolimus and cyclosporine, where genetic variants impact dosing due to altered metabolism rates. This enzyme also affects the metabolism and effectiveness of other drugs such as itraconazole, statins (simvastatin and atorvastatin), apixaban, vincristine, ondansetron, atazanavir, and fentanyl, which in turn influences their therapeutic outcomes and risk profiles.

**SLC22A10**: The gene SLC22A10 is involved in the kidney's ability to excrete various drugs and substances, influencing the pharmacokinetics of these drugs by affecting their clearance from the body. Genetic variations in SLC22A10 can alter the effectiveness and safety of drugs that are cleared renally, such as certain diuretics or antibiotics, potentially necessitating dose adjustments to avoid toxicity or ineffective treatment.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**HLA-E**: The gene HLA-E, which plays a significant role in immune system regulation, may interact pharmacodynamically with methotrexate, a drug used for autoimmune diseases and cancer. This interaction likely occurs as methotrexate modulates immune responses that are under the control of HLA-E, affecting drug efficacy and potential adverse effects rather than affecting the drug's absorption, distribution, metabolism, or excretion.

**SLC22A7**: Genetic variations in the SLC22A7 gene, which encodes for the Organic Anion Transporter 3 (OAT3), significantly affect the renal excretion and therefore the clearance, efficacy, and toxicity of various drugs such as cefotaxime, oseltamivir, doxorubicin, daunorubicin, and capecitabine. These interactions might influence not just the pharmacokinetics but also the therapeutic and toxic effects of these drugs due to the role of OAT3 in altering their availability at cellular or tissue levels.

**HLA-G**: HLA-G's potential pharmacodynamic interactions with drugs like fluorouracil, irinotecan, methotrexate, and capecitabine, primarily used in chemotherapy, relate to its role in modulating immune responses which could influence the immune system's ability to recognize and destroy tumor cells. These interactions likely result from HLA-G enhancing immune evasion capabilities in cancer cells, thereby potentially modifying the therapeutic efficacy of the mentioned drugs.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**HLA-DRA**: The HLA-DRA gene, though not directly interacting with drugs through pharmacokinetic pathways, plays an indirect role in pharmacodynamics due to its involvement in the immune system. It is implicated in the immune-mediated drug reactions, such as hypersensitivities to antibiotics like amoxicillin, flucloxacillin, and clavulanate, possibly by affecting how drug-related antigens are presented to the immune system by antigen-presenting cells, thereby influencing the likelihood or severity of allergic reactions.

**HLA-DRB1**: The HLA-DRB1 gene, through its various alleles, significantly influences the pharmacogenetic interactions that affect the efficacy and safety of medications, causing immune-mediated hypersensitivity reactions. For instance, the HLA-DRB1*15:01 allele is linked to abacavir hypersensitivity in HIV treatment, while HLA-DRB1*07:01 is associated with hepatic injuries from ximelagatran, highlighting the importance of understanding a patient's HLA-DRB1 allele status to optimize and personalize treatment strategies.

**ABCC5**: ABCC5, an efflux transporter gene, influences the pharmacokinetics and pharmacodynamics of several drugs, notably altering the bioavailability and systemic toxicity of doxorubicin, a key cancer chemotherapy drug. Other drugs such as glyburide, leucovorin, cannabidiol, irinotecan, and fluorouracil are also likely affected by ABCC5's capacity to modulate drug levels, either impacting their therapeutic efficacy or altering their toxicity profile.

**SLC22A13**: SLC22A13, a transporter protein involved in the cellular uptake and removal of organic cations in the kidney and liver, may impact the pharmacokinetics of cationic drugs like metformin or certain antivirals by affecting how these drugs are absorbed, distributed, metabolized, or excreted. Genetic variants in SLC22A13 could lead to altered drug levels in the body, where reduced function might increase drug toxicity due to decreased clearance, and enhanced function could lower drug efficacy with increased clearance.

**NR1I2**: NR1I2, or pregnane X receptor (PXR), regulates genes encoding drug-metabolizing enzymes and transport systems like CYP3A4 and MDR1, influencing the pharmacokinetics of various drugs. Activators of NR1I2 such as rifampin and carbamazepine can increase the metabolism and decrease the efficacy of drugs like sirolimus and rosuvastatin by upregulating CYP3A4, while inhibitors can slow metabolism, increasing toxicity risk.

**RUNDC3B**: Although the gene RUNDC3B is primarily involved in intracellular trafficking, its potential pharmacogenetic interaction with imatinib, a tyrosine kinase inhibitor used in cancer treatment, remains speculative. Given RUNDC3B's role in cellular dynamics, there is a possibility that it could influence the intracellular concentration and efficacy of imatinib in cancer cells, particularly those with varying expressions of RUNDC3B; however, this interaction lacks concrete evidence and is still under exploration.

**HLA-DQB1**: HLA-DQB1 gene variants significantly impact drug hypersensitivity reactions, particularly for drugs like abacavir, allopurinol, nevirapine, lamotrigine, and carbamazepine, which can cause severe reactions such as Steven-Johnson syndrome and toxic epidermal necrolysis in genetically predisposed individuals. These interactions emphasize the role of HLA-DQB1 in pharmacodynamics, affecting drug safety and efficacy rather than drug metabolism.

**SLCO1B3**: SLCO1B3, which encodes the organic anion transporting polypeptide 1B3 (OATP1B3), plays a crucial role in the hepatic uptake and metabolism of several drugs including docetaxel, mycophenolate mofetil, telmisartan, and voriconazole, affecting their plasma levels, therapeutic effects, and toxicity. Variants in this gene can modify the transport efficiency of these drugs, influencing their absorption, distribution, elimination, and overall pharmacokinetics, thereby necessitating tailored dosing in personalized medicine to enhance efficacy and reduce adverse effects.

**CYP2J2**: CYP2J2, primarily involved in metabolizing polyunsaturated fatty acids affecting cardiovascular physiology, does not have well-documented direct pharmacokinetic interactions with drugs like mycophenolate mofetil and tacrolimus. However, its role in modulating vascular tone and inflammation could potentially influence the pharmacodynamics of these immunosuppressive drugs used in organ transplantation and autoimmune diseases, despite the lack of a direct metabolic pathway involving CYP2J2.

**ABCC1**: ABCC1, a critical gene encoding for an efflux transporter, significantly affects the pharmacokinetics and pharmacodynamics of various drugs by impacting their absorption, distribution, and elimination. Notably, it modulates the clearance of anticancer drugs like SN-38 and doxorubicin from cells, contributing to drug resistance and variability in therapeutic efficacy and toxicity, which is particularly relevant in optimizing cancer chemotherapy. Other drugs such as vincristine, methotrexate, and ritonavir, among others, also demonstrate pharmacogenetic interactions with ABCC1, affecting treatment outcomes especially in oncology.

**SLC22A9**: SLC22A9 is crucial in the pharmacokinetics of drugs that interact with bile acid pathways, influencing the hepatic uptake and clearance of various compounds, although specific drugs affected by this gene remain speculative due to its role in bile acid transport. Understanding the gene's effect could significantly influence therapeutic strategies and drug dosing management, particularly for drugs like statins and ursodeoxycholic acid, which are heavily involved in liver metabolism and bile acid transportation.

**ABCC11**: The ABCC11 gene, known for facilitating ATP-dependent transport across cellular membranes, significantly affects the pharmacokinetics of anticancer drugs like fluorouracil and capecitabine by varying the efficiency of drug metabolite expulsion from cells. Different ABCC11 genetic variants lead to changes in drug bioavailability and toxicity, which affects the efficacy and side effects experienced by patients, making it pivotal for customizing cancer treatment protocols.

**NAT2**: The NAT2 gene encodes an enzyme crucial for the metabolism of various drugs through N-acetylation, influencing their pharmacokinetics and toxicity. Variants in NAT2 affect the metabolism of drugs like isoniazid, hydralazine, procainamide, sulfamethoxazole, and pyrazinamide, leading to differences in acetylator status (rapid, intermediate, slow) among individuals, which impacts drug plasma levels, exposure duration, and risk of adverse effects such as increased toxicity and drug-induced lupus.

**HLA-DQA1**: Specific HLA-DQA1 alleles are linked to drug-induced hypersensitivity reactions with medications such as abacavir, flucloxacillin, lumiracoxib, and others. These alleles influence the immune system's response to these drugs, leading to heightened or adverse reactions, emphasizing the role of HLA-DQA1 in modulating the immune response to certain medications.

**CYP21A2**: The pharmacogenetic interactions of CYP21A2 focus on its role in managing congenital adrenal hyperplasia (CAH), where mutations in this gene affect enzyme activity crucial for steroid biosynthesis. This dictates the use of tailored glucocorticoid therapy, using drugs like hydrocortisone in children and prednisone or dexamethasone in adults, and fludrocortisone for aldosterone deficiency. Treatment adjustmentsâ€”including the choice and dosage of medicationâ€”are essential based on specific CYP21A2 mutations to avoid negative effects such as growth suppression or insufficient control of androgen excess.

**SLC22A11**: The gene SLC22A11 encodes for the organic anion transporter 4 (OAT4), which significantly impacts the renal excretion of drugs such as diuretics like furosemide and thiazide, influencing their effectiveness and potential for toxicity. Alterations in SLC22A11 also affect the clearance of methotrexate, a chemotherapeutic and immunosuppressant agent, primarily through modified drug transport, which could lead to changes in its pharmacokinetic profile despite not directly influencing its metabolism.

**CYP2R1**: Variations in the CYP2R1 gene can affect the efficiency of vitamin D metabolism by altering the enzyme's ability to convert vitamin D into 25-hydroxyvitamin D, influencing the effectiveness of vitamin D supplementation. Additionally, interactions between CYP2R1 and ribavirin don't involve direct metabolism by the enzyme but may involve indirect effects related to ribavirinâ€™s impact on vitamin D levels or bone health, potentially affecting treatment outcomes in conditions like chronic hepatitis C.

**ABCB11**: The gene ABCB11, which codes for the bile salt export pump (BSEP), significantly influences the pharmacokinetics of several drugs, including rosuvastatin, ribavirin, odevixibat, and glyburide, by affecting their hepatic uptake, biliary excretion, or both. Variants in ABCB11 may alter the efficacy and toxicity of these medications, highlighting its importance in personalized drug therapy.

**HFE**: Epoetin alfa, used for anemia in chronic kidney disease, interacts with HFE gene variants, affecting iron utilization and metabolism, thereby influencing the drug's pharmacokinetics. Conversely, pazopanib, a cancer therapy drug, may have non-pharmacokinetic interactions with the HFE gene by affecting iron metabolic pathways, though the exact mechanism is less clear.

**CYP2C8**: The CYP2C8 gene plays a crucial role in metabolizing various medications such as paclitaxel, pioglitazone, repaglinide, and amodiaquine, affecting their efficacy and toxicity due to genetic variations that influence drug metabolism and exposure. These interactions, involving pharmacokinetic processes, suggest that CYP2C8 genetic testing could be utilized to optimize drug dosing and reduce toxicity.

**SLC2A9**: Variations in the SLC2A9 gene, which encodes the GLUT9 uric acid transporter, affect the pharmacodynamics of allopurinol and potentially the mechanism of furosemide in managing conditions related to uric acid levels. Allopurinol's effectiveness can vary based on SLC2A9 polymorphisms that influence uric acid levels, requiring dosage adjustments, while the impact of SLC2A9 on furosemide primarily involves changes in uric acid excretion, though the exact process needs clarification.

**HLA-DPB1**: HLA-DPB1, a gene expressed in antigen-presenting cells, primarily affects drug hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) through immune modulation, particularly in pharmacodynamic interactions. For example, its specific alleles may increase the risk of agranulocytosis in patients treated with the antipsychotic drug clozapine, while there is no confirmed pharmacogenetic interaction between HLA-DPB1 and aspirin.

**CYP4B1**: CYP4B1, which is involved in the metabolism of fatty acids and xenobiotics, may potentially interact with drugs like docetaxel and thalidomide due to their structural similarities to fatty acids. This interaction could alter the pharmacokinetics of these drugs, affecting their efficacy and safety, although direct evidence of this is currently limited.

**HLA-DPA1**: HLA-DPA1 influences immune responses and plays a significant role in hypersensitivity to drugs such as abacavir, used in HIV treatment, due to its function in antigen presentation and subsequent immune activation. While it doesnâ€™t affect the metabolism or elimination of aspirin, it may impact the immune-mediated adverse reactions to aspirin, suggesting a potential pharmacodynamic interaction through modulation of inflammatory pathways.
